TY  - JOUR
AU  - Mattiuzzi, Camilla
AU  - Henry, Brandon M.
AU  - Sanchis-Gomar, Fabian
AU  - Lippi, Giuseppe
PY  - 2020/09/07
Y2  - 2023/02/27
TI  - SARS-CoV-2 recurrent RNA positivity after recovering from coronavirus disease 2019 (COVID-19): a meta-analysis
JF  - Acta Biomedica Atenei Parmensis
JA  - Acta Biomed
VL  - 91
IS  - 3
SE  - ORIGINAL INVESTIGATIONS/COMMENTARIES - SPECIAL COVID19 
DO  - 10.23750/abm.v91i3.10303
UR  - https://mattioli1885journals.com/index.php/actabiomedica/article/view/10303
SP  - e2020014
AB  - &lt;p class=&quot;p1&quot;&gt;&lt;em&gt;Background and aim:&lt;/em&gt; Isolation of subjects with active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is a pivotal preventive measure in the ongoing coronavirus disease 2019 (COVID-19) pandemic. A growing number of studies reported cases of recurrent SARS-CoV-2 RNA positivity following disease recovery, which were identified with a critical literature search and then meta-analyzed in this article. &lt;em&gt;Materials and Methods:&lt;/em&gt; A digital search was performed in Medline and Web of Science, using the keywords “coronavirus disease 2019” OR “COVID-19” OR “severe acute respiratory disease 2” OR “SARS-CoV-2” AND “recurrence” OR “repositivization” OR “retesting”, without date or language restrictions. Recovery was defined as resolution of symptoms, with at least two consecutive negative molecular tests. &lt;em&gt;Results:&lt;/em&gt; A total number of 17 studies, with 5,182 COVID-19 patients, were included. SARS-CoV-2 recurrent RNA positivity in recovered COVID-19 patients ranged between 7-23% across the studies, with follow-up testing between 1-60 days. The estimated cumulative rate of SARS-CoV-2 recurrent RNA positivity was 12% (95% confidence interval, 12-13%; I&lt;sup&gt;2&lt;/sup&gt;, 74%). &lt;em&gt;Conclusions:&lt;/em&gt; Repeated molecular testing on respiratory tracts specimens at 1 and 2 months after recovery from COVID-19 is strongly advisable for early identification, isolation and clinical management of subjects with SARS-CoV-2 recurrent RNA positivity.&lt;/p&gt;
ER  -